Discontinuation of tyrosine kinase inhibitor (TKI) therapy for chronic myeloid (CML) leukaemia patients is largely as successful in real-world clinical practice as it is in clinical trial settings, according to a new study conducted in Sweden. “Initially considered to be a lifelong treatment, several TKI discontinuation trials have shown that approximately 40–50% of patients with ...
TKI discontinuation in routine practice matches success in clinical trial settings for CML: Study
By Dave Levitan
12 Apr 2021